Celltrion Inc, v. F. Hoffmann-La Roche AG, Biogen Inc. and Genentech Inc., District Court of the Hague, 27 September 2017, Case No. ECLI:NL:RBDHA:2017:11301

Patent revoked due to lack of novelty. Priority can not be invoked since the priority right was not validly transferred.

A copy of the decision can be read here.